Sophia Schuman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sophia Schuman has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Conan G. Kinsey
Department of Oncological Sciences, University of Utah
15 shared publications - Martin McMahon
Huntsman Cancer Institute
15 shared publications - Adam J. Dupuy
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
14 shared publications - Alistair G. Rust
European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge, UK
14 shared publications - Allie H. Grossmann
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
14 shared publications - Annie Liu
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
14 shared publications
Latest Publications
- Open Access
- 20 November 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (10) , 1378-1387
Risk of Cancer Diagnosis in Patients With Eosinophilic Esophagitis Using a Nationwide Swedish Population Cohort
Background: Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease of the esophagus. Chronic inflammation has been linked to cancer development. We aimed to study the potential association between EoE and later cancer diagnosis. Methods: In this nationwide population‐based cohort study, we identified 1580 individuals with EoE diagnosed between 1990–2017 through Sweden's 28 pathology departments. Up to five general population reference individuals were matched on age and sex ( n = 7533). A Cox regression analysis estimated adjusted hazard ratios (aHRs) for cancer up until December 31, 2020. To reduce potential intrafamilial confounding, we also compared EoE individuals with their unaffected siblings. Results: During a median follow‐up of 7 years, 47 individuals with EoE (3.9/1000 person‐years) developed cancer versus 183 (3.2/1000 person‐years) reference individuals. This corresponded to a non‐significant aHR of 1.11 (95% CI = 0.80–1.53). Incidence rates were independent of budesonide and proton‐pump inhibitor use. Individuals with EoE however did have an increased risk of esophageal cancer where two EoE versus one reference individual were diagnosed (aHR = 25.20; 95% CI = 2.28–278.80), and also Barrett's esophagus risk was also increased in EoE (HR = 18.18; 95% CI = 6.75–48.95). Non‐esophageal gastrointestinal (GI) cancer occurred in 11 EoE versus 24 reference individuals: aHR = 2.03 (95% CI = 0.99–4.18). We found no increased risk of cancers from the skin (EoE n = 10), lung ( n = 0), breast ( n = 4), or blood ( n = 0). Sibling analyses supported these findings. Conclusion: We did not find any overall association between EoE and cancer development. EoE was associated with esophageal cancer, but this was very rare with wide confidence interval and few cases therefore we urge caution with generalization of these findings.
- 20 November 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (10) , 1378-1387
Open AccessRisk of Cancer Diagnosis in Patients With Eosinophilic Esophagitis Using a Nationwide Swedish Population Cohort
Background: Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease of the esophagus. Chronic inflammation has been linked to cancer development. We aimed to study the potential association between EoE and later cancer diagnosis. Methods: In this nationwide population‐based cohort study, we identified 1580 individuals with EoE diagnosed between 1990–2017 through Sweden's 28 pathology departments. Up to five general population reference individuals were matched on age and sex ( n = 7533). A Cox regression analysis estimated adjusted hazard ratios (aHRs) for cancer up until December 31, 2020. To reduce potential intrafamilial confounding, we also compared EoE individuals with their unaffected siblings. Results: During a median follow‐up of 7 years, 47 individuals with EoE (3.9/1000 person‐years) developed cancer versus 183 (3.2/1000 person‐years) reference individuals. This corresponded to a non‐significant aHR of 1.11 (95% CI = 0.80–1.53). Incidence rates were independent of budesonide and proton‐pump inhibitor use. Individuals with EoE however did have an increased risk of esophageal cancer where two EoE versus one reference individual were diagnosed (aHR = 25.20; 95% CI = 2.28–278.80), and also Barrett's esophagus risk was also increased in EoE (HR = 18.18; 95% CI = 6.75–48.95). Non‐esophageal gastrointestinal (GI) cancer occurred in 11 EoE versus 24 reference individuals: aHR = 2.03 (95% CI = 0.99–4.18). We found no increased risk of cancers from the skin (EoE n = 10), lung ( n = 0), breast ( n = 4), or blood ( n = 0). Sibling analyses supported these findings. Conclusion: We did not find any overall association between EoE and cancer development. EoE was associated with esophageal cancer, but this was very rare with wide confidence interval and few cases therefore we urge caution with generalization of these findings.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis